ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 1104 for:    translate

Brief Reminders as Intervention for Greater Engagement of Cochrane Translators

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03534791
Recruitment Status : Recruiting
First Posted : May 23, 2018
Last Update Posted : May 23, 2018
Sponsor:
Collaborator:
Croatian Science Foundation
Information provided by (Responsible Party):
Dalibora Behmen, University of Split, School of Medicine

Brief Summary:
The intervention will consist of reminders which will be send to the participants randomly via email, with aim to increase the frequency and amount of translated plain language summaries (PLS).

Condition or disease Intervention/treatment Phase
Knowledge Translation Other: Reminders Not Applicable

Detailed Description:

All study participants who accept participation in the study will be initially assigned 3 PLSs, and subsequently they will be assigned more PLSs when they translated the previous ones. Intervention group will receive one customized e-mail reminder two weeks after the PLS assignment if they do not translate it within two weeks. If they still do not translate the PLS, they will receive another customized e-mail reminder after every two weeks until they translate the PLS or until we reach maximum of 4 bi-weekly reminders (at 2 weeks, 4 weeks, 6 weeks and 8 weeks post-assignment) or until participants indicate that they are unable to translate it anymore. Text of the reminder that will be sent to the study participants is available in Supplementary file 1. The reminders will be customized for each PLS, and they will contain a name of the PLS indicated in the message. If the participants do not translate PLS within 2 months from PLS assignment, we will stop sending them reminders and we will consider them as dropouts.

Control group will receive no intervention, i.e. standard procedure. Participants in the control group will receive PLSs for translation, in the frequency they indicated, and they will not receive any reminders. They will be assigned new PLSs once they translate the ones that were previously assigned.

All PLSs will be translated in Memsource, a translation management tool that Cochrane plans to start using since March 2018 for managing translation of summaries. Participants will be followed 6 months from the moment of allocation.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

All study participants who accept participation in the study will be initially assigned 3 PLSs, and subsequently they will be assigned more PLSs when they translated the previous ones. Intervention group will receive one customized e-mail reminder two weeks after the PLS assignment if they do not translate it within two weeks.

Control group will receive no intervention, i.e. standard procedure. Participants in the control group will receive PLSs for translation, in the frequency they indicated, and they will not receive any reminders. They will be assigned new PLSs once they translate the ones that were previously assigned.

Masking: Double (Participant, Outcomes Assessor)
Masking Description: Study participants will be blinded to allocation. The author who will communicate with the participants will not be blinded. Other authors and outcome assessors who will analyze data will be blinded to allocation of study participants; anonymized data will be analyzed.
Primary Purpose: Treatment
Official Title: Interventions for Increasing Volunteer Engagement in Knowledge Translation Activity of Translating Cochrane Plain Language Summaries: a Randomized Controlled Trial
Actual Study Start Date : May 1, 2018
Estimated Primary Completion Date : December 1, 2018
Estimated Study Completion Date : March 1, 2019

Arm Intervention/treatment
Experimental: Reminders
Reminders customized for each PLS, containing a name of the PLS indicated in the message. If the participants do not translate PLS within 2 months from PLS assignment, we will stop sending them reminders and we will consider them as dropouts.
Other: Reminders
Personalized email which will aim for reminding of the translator about the PLSs on hold.

No Intervention: Control group
Control group will receive no intervention, i.e. standard procedure. Participants in the control group will receive PLSs for translation, in the frequency they indicated, and they will not receive any reminders. They will be assigned new PLSs once they translate the ones that were previously assigned.



Primary Outcome Measures :
  1. Number of translated PLSs within the 6 month follow-up [ Time Frame: 6 months ]
    The number of translated PLSs will be scored in the six months period for a participant


Secondary Outcome Measures :
  1. Number of translated PLSs after 3 months of follow up [ Time Frame: 3 months ]
    The number of translated PLSs will be scored in the three months period for a participant

  2. Time to submitting translation [ Time Frame: 6 months ]
    The investigators will note the time needed to submit translation

  3. Satisfaction with participation in the translation project [ Time Frame: 6 months ]
    Likert type scale from 1 to 10 (ranging from 1-completely unsatisfactory to 10-completely satisfactory)

  4. Loss of participants [ Time Frame: 6 months ]
    Loss of participants from the trial at final follow-up of 6 months, defined as participants' message that they wish to stop translating during the trial period, without later messages during the trial that they wish to engage in translation again.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • adults ≥18 years who volunteered to translate Cochrane PLSs within the Croatian translation project.

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03534791


Contacts
Contact: Dalibora Behmen, Professor +385 21 557923 dalibora.behmen@mefst.hr
Contact: Livia Puljak, PhD livia@mefst.hr

Locations
Croatia
University of Split School of Medicine Recruiting
Split, Split-Dalmatia County, Croatia, 21000
Contact: Lana Barać, PhD       lana.barac@mefst.hr   
Contact: Livia Puljak, PhD       livia@mefst.hr   
Sponsors and Collaborators
University of Split, School of Medicine
Croatian Science Foundation
Investigators
Principal Investigator: Dalibora Behmen, Professor Researcher and administrator

Responsible Party: Dalibora Behmen, Professor, University of Split, School of Medicine
ClinicalTrials.gov Identifier: NCT03534791     History of Changes
Other Study ID Numbers: 2014- 09-7672
First Posted: May 23, 2018    Key Record Dates
Last Update Posted: May 23, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Raw data will be posted to the Figshare repository (https://figshare.com/)
Time Frame: Within 12 months from study completion. The data will remain in the public repository indefinitely.
Access Criteria: Open access, publicly available

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No